Protein instability and immunogenicity: Roadblocks to clinical application of injectable protein delivery systems for sustained release

Journal of Pharmaceutical Sciences

Volumn 101, Issue 3, 2012, Pages 946-954

  Jiskoot, Wim ^a   Randolph, Theodore W ^b   Volkin, David B ^c   Middaugh, C Russell ^c   Schöneich, Christian ^c   Winter, Gerhard ^d   Friess, Wolfgang ^d   Crommelin, Daan J A ^e   Carpenter, John F ^f  

^a LEIDEN UNIVERSITY   (Netherlands)

^b UCB 450   (United States)

^c UNIVERSITY OF KANSAS   (United States)

^d UNIVERSITY OF MUNICH   (Germany)

^e UTRECHT UNIVERSITY   (Netherlands)

^f UNIVERSITY OF COLORADO   (United States)

Author keywords

Drug delivery systems; Immunogenicity; Liposomes; Physicochemical characterization; PLGA; Polymers; Protein delivery; Stability; Therapeutic proteins

Indexed keywords

CHITOSAN; LIPOSOME; PROTEIN;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MANUFACTURE; DRUG STORAGE; IMMUNOGENICITY; IN VIVO STUDY; MEDICAL RESEARCH; MICROPARTICLE ENZYME IMMUNOASSAY; PROTEIN DEGRADATION; PROTEIN STABILITY; QUANTITATIVE ANALYSIS; SUSTAINED DRUG RELEASE;

EID: 84855872738     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23018     Document Type: Note

References (37)

1. Wischke C, Schwendeman SP. 2008. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int J Pharm 364(2):298-327.
2. ICH Harmonised Tripartite Guideline M4Q(R1). 2002. The common technical document for the registration of pharmaceuticals for human use: Module 3: Quality.
3. Rosenberg AS. 2006. Effects of protein aggregates: An immunologic perspective. AAPS J 8(3):E501-E507.
4. Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJA, Middaugh CR, Winter G, Fan Y-X, Kirshner S, Verthelyi D, Kozlowski S, Clouse KA, Swann PG, Rosenberg A, Cherney B. 2009. Overlooking subvisible particles in therapeutic protein products: Gaps that may compromise product quality. J Pharm Sci 98(4):1201-1205.
5. Den Engelsman J, Garidel P, Smulders R, Mahler H-C, Koll H, Smith B, Bassarab S, Seidl A, Hainzl O, Jiskoot W. 2011. Strategies for the assessment of protein aggregates in pharmaceutical biotech product development. Pharm Res 28(4):920-933.
6. Jiskoot W, van Schie RMF, Carstens MG, Schellekens H. 2009. Immunological risk of injectable drug delivery systems. Pharm Res 26(6):1303-1314.
7. Gupta RK, Siber GR. 1995. Adjuvants for human vaccines-Current status, problems and future prospects. Vaccine 13(14):1263-1276.
8. Waeckerle-Men Y, Allmen EU, Gander B, Scandella E, Schlosser E, Schmidtke G, Merkle HP, Groettrup M. 2006. Encapsulation of proteins and peptides into biodegradable poly(d, l-lactide-co-glycolide) microspheres prolongs and enhances antigen presentation by human dendritic cells. Vaccine 24(11):1847-1857.
9. Sharp F, Ruane D, Claass B, Creagh E, Harris J, Malyala P, Singh M, O'Hagan DT, Pétrilli V, Tschopp J, O'Neill LAJ, Lavelle EC. 2009. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci U S A 106(3):870-875.
10. Akagi T, Shima F, Akashi M. 2011. Intracellular degradation and distribution of protein-encapsulated amphiphilic poly(amino acid) nanoparticles. Biomaterials 32(21):4959-4967.
11. De Temmerman M, Rejman J, Demeester J, Irvine DJ, Gander B, De Smedt SC. 2011. Particulate vaccines: On the quest for optimal delivery and immune response. Drug Discov Today 16(13-14):569-582.
12. Torres M, Wilson-Welder JH, Lopac SK, Phanse Y, Carrillo-Conde B, Ramer-Tait AE, Bellaire BH, Wannemuehler MJ, Narasimhan B. 2011. Polyanhydride microparticles enhance dendritic cell antigen presentation and activation. Acta Biomaterialia 7(7):2857-2864.
13. Singh M, Chakrapani A, O'Hagan D. 2007. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev Vaccines 6(5):797-808.
14. Peek LJ, Middaugh CR, Berkland C. 2008. Nanotechnology in vaccine delivery. Adv Drug Deliv Rev 60(8):915-928.
15. Arca HC, Gunbeyaz M, Senel S. 2009. Chitosan-based systems for the delivery of vaccine antigens. Expert Rev Vaccines 8(7):937-953.
16. Krishnamachari Y, Geary SN, Lemke CD, Salem AK. 2011. Nanoparticle delivery systems in cancer vaccines. Pharm Res 28(2):215-236.
17. Garland SM, Smith JS. 2010. Human papillomavirus vaccines: Current status and future prospects. Drugs 70(9):1079-1098.
18. Villa LL. 2011. HPV prophylactic vaccination: The first years and what to expect from now. Cancer Lett 305(2):106-112.
19. Amidi M, Mastrobattista E, Jiskoot W, Hennink W. 2010. Chitosan-based delivery systems for protein therapeutics and antigens. Adv Drug Deliv Rev 62(1):59-82.
20. Bal S, Slütter B, van Riet E, Kruithof A, Ding Z, Jiskoot W, Bouwstra JA. 2010. Efficient induction of immune responses through intradermal vaccination with N-trimethyl chitosan containing antigen formulations. J Control Release 142(3):374-383.
21. Filipe V, Hawe A, Jiskoot W. 2010. Critical evaluation of nanoparticle tracking analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm Res 27(5):796-810.
22. Cherney B. 2011. Scientific and regulatory considerations for stability studies: Beyond current FDA guidance. Podium presentation, 2011 Colorado Protein Stability Conference. July 19-21, Breckenridge, Colorado.
23. Philo JS. 2009. A critical review of methods for size characterization of non-particulate protein aggregates. Curr Pharm Biotechnol 10(4):359-372.
24. Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJ, Middaugh CR, Winter G. 2010. Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: Essential need to use orthogonal methods to assure the quality of therapeutic protein products. J Pharm Sci 99(5):2200-2208.
25. Bond MD, Panek ME, Zhang Z, Wang D, Mehndiratta P, Zhao H, Gunton K, Ni A, Nedved ML, Burman S, Volkin DB. 2010. Evaluation of a dual-wavelength size exclusion HPLC method with improved sensitivity to detect protein aggregates and its use to better characterize degradation pathways of an IgG1 monoclonal antibody. J Pharm Sci 99(6):2582-2597.
26. Van de Weert M, Hennink WE, Jiskoot W. 2000. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm Res 17(10):1159-1167.
27. Carpenter JF, Pikal MJ, Chang BS, Randolph TW. 1997. Rational design of stable lyophilized protein formulations: Some practical advice. Parm Res 14(8):969-975.
28. Tang XL, Pikal MJ. 2004. Design of freeze-drying processes for pharmaceuticals: Practical advice. Pharm Res 21(2):191-200.
29. Tan ML, Choong PFM, Dass CR. 2010. Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery. Peptides 31(1):184-193.
30. Lee KY, Yuk SH. 2007. Polymeric protein delivery systems. Prog Polym Sci 32(7):669-697.
31. Van Tomme SR, Hennink WE. 2007. Biodegradable dextran hydrogels for protein delivery applications. Expert Rev Med Devices 4(2):147-164.
32. Seyednejad H, Ghassemi AH, van Nostrum CF, Vermonden T, Hennink WE. 2011. Functional aliphatic polyesters for biomedical and pharmaceutical applications. J Control Release 152(1):168-176.
33. Kamerzell TJ, Esfandiary R, Joshi SB, Middaugh CR, Volkin DB. 2011. Protein-excipient interactions: Mechanisms and biophysical characterization applied to protein formulation development. Adv Drug Deliv Rev 63:1118-1159.AU: The volume number and page range have been updated as per PubMed. Please check.
34. Katzenstein GE, Vrona SA, Wechsler RJ, Steadman BL, Lewis RV, Middaugh CR. 1986. Role of conformational changes in the elution of proteins from reversed-phase HPLC columns. Proc Natl Acad Sci U S A 83(12):4268-4272.
35. Jones LS, Peek LJ, Power J, Markham A, Yazzie B, Middaugh CR. 2005. Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens. J Biol Chem 280(14):13406-13414.
36. Hawe A, Sutter M, Jiskoot W. 2008. Extrinsic fluorescent dyes as tools for protein characterization. Pharm Res 25(7):1487-1499.
37. Shi L, Caulfield MJ, Chern RT, Wilson RA, Sanyal G, Volkin DB. 2002. Pharmaceutical and immunological evaluation of a single-shot hepatitis B vaccine formulated with PLGA microspheres. J Pharm Sci 91(4):1019-1035.